Revised. Amendments from Version 1
==================================

Following reviewers comments, the authors have modified the mansucript to reflect their views. The no primary antibody (NPA) data has been added to Fig 3 and an additional datafile added for the whole slide image. The authors feel that the the persistant stromal staining demonstrates a limitation in the Tamoxifen-induced knockout model and not a non-specific binding of the antibody. This has been explained further in the conclusions section of the article.

Introduction
============

ARID1A (AT-rich interactive domain 1a) is a member of the SWI/SNF family and its loss has been implicated as a factor in multiple premalignant and malignant conditions, including Barrett's oesophagus and oesophageal carcinoma as well as endometrial and clear cell ovarian carcinomas and their precursor endometriotic lesions ^[@ref-1]--\ [@ref-4]^. The ARID1A antibody from Human Protein Atlas is a rabbit antibody generated against a PrEST (Protein Epitope Signature Tag) fragment of the ARID1A gene and affinity purified against the same fragment ^[@ref-5]^. It is thus designated as being "mono-specific" in that the affinity purification removes any non-specific or low affinity binders to the peptide. Through the Human Protein Atlas, the antibody has been tested on a wide variety of human tissue types and human malignancies, as well as for expression in immunofluorescence on U-2 OS, A-431 and U-251 MG cell lines. This demonstrates a nuclear expression in all cell lines and in the majority of tissue types ^[@ref-6]^. However, the Western blot data were not supportive and did not produce staining corresponding to the expected size, although the data from a protein array did confirm a peak at the expected size. The antibody has been used to stain human colorectal cancers ^[@ref-7]^, clear cell carcinomas ^[@ref-8]^ and on a variety of clear cell cancer cell lines ^[@ref-9]^ by immunohistochemistry.

To our knowledge, whilst the sequence homology between mouse and human ARID1A is 95%, this antibody has not been qualified using knockout tissue and has not been tested or published on murine tissue and this work represents the first data to do so.

Materials and methods
=====================

Reagent details
---------------

Details of all reagents with reference to the immunohistochemical staining procedure can be found in [Table 1](#T1){ref-type="table"}.

###### Details of ancillary reagents for immunohistochemistry.

  Process                   Reagent                         Manufacturer       Catalogue Number   Concentration
  ------------------------- ------------------------------- ------------------ ------------------ ---------------
  Fixation                  Neutral Buffered Formaldehyde   Sigma              HT501128           10%
  Pretreatment              ER1 (Sodium Citrate, pH6)       Leica Biosystems   AR9961             Proprietary
  ER2 (Tris/EDTA, pH9)      Leica Biosystems                AR9640             Proprietary        
  Enzyme 1 (Proteinase K)   Leica Biosystems                AR9551             100 µg/ml          
  Staining                  Peroxide Block                  Leica Biosystems   DS9263             Proprietary
  Streptavidin -- HRP       Leica Biosystems                DS9263             Proprietary        
  Diaminobenizidine (DAB)   Leica Biosystems                DS9263             Proprietary        
  Haematoxylin              Leica Biosystems                DS9263             Proprietary        
  DAB Enhancer              Leica Biosystems                AR9452             Proprietary        
  Washes/Blocks             Bond Wash (Tris Buffer)         Leica Biosystems   AR9590             Proprietary
  Antibody Diluent          Leica Biosystems                AR9352             Proprietary        
  Avidin/Biotin Block       Vector Laboratories             SP-2001            Proprietary        

Antibody details
----------------

Anti-ARID1A is a monospecific rabbit polyclonal generated to a PrEST sequence -- PGLGNVAMGPRQHYPYGGPYDRVRTEPGIGPEGNMSTGAPQPNLMPSNPDSGMYSPSRYPPQQQQQQQQRHDSYGNQFSTQGTPSGSPFPSQQTTMYQQQQQNYK ( [Table 2](#T2){ref-type="table"}). The homology of the PrEST sequence used as immunogen is 95%, when verified with BLAST against the mouse sequence. The lot number used for all validations was A40072 and for subsequent staining was D81856. A concentration of 1 µg/ml was used for initial validations and 0.5 µg/ml for final runs.

###### Details of primary and secondary antibodies.

  Antibody                       Manufacturer             Catalogue Number   RRID
  ------------------------------ ------------------------ ------------------ -------------
  ARID1A                         Atlas Antibodies         HPA005456          AB_1078205
  GAPDH (Clone 14C10)            Cell Signaling           2118               AB_561053
  Donkey anti-Rabbit Biotin      Jackson Immunoresearch   711-065-152        AB_2333077
  Goat anti-Rabbit IRDye 680LT   Li-Cor Biosciences       926-68021          AB_10706309
  Goat anti-Rabbit IRDye 800CW   Li-Cor Biosciences       926-32213          AB_621848

Donkey anti-rabbit biotin (Jackson Immunoresearch, [Table 2](#T2){ref-type="table"}) is specific for Rabbit IgG (Heavy and Light chains) and was affinity purified to remove cross-reactions to Bovine, Chicken, Goat, Guinea Pig, Syrian Hamster, Horse, Human, Mouse, Rat and Sheep. All slides were stained with a concentration of 4.8 µg/ml.

Anti-GAPDH was used as a loading control for Western blots and was a rabbit monoclonal (Cell Signaling, [Table 2](#T2){ref-type="table"}). Detection antibody for the Western blot for ARID1a was Goat anti-rabbit IR Dye 680LT (Li-Cor Biosciences, [Table 2](#T2){ref-type="table"}) used at a concentration of 0.1 µg/ml and detection of GAPDH was Goat anti-rabbit IR Dye 800CW (Li-Cor Biosciences, [Table 2](#T2){ref-type="table"}).

Tissue details
--------------

All tissues and cell pellets used during the validation were fixed in Neutral Buffered Formaldehyde as specified ( [Table 3](#T3){ref-type="table"}) before being transferred directly to 70% ethanol for no longer than 3 days. Tissue processing was conducted on a Leica ASP300 through graded ethanols before clearing in xylene and impregnation in molten paraffin wax (Fisher). All tissue sections were cut on a Leica rotary microtome at 3 µm.

Arid 1a ^-/-^ mice were created by crossing Floxed *Arid1a* mice with *ROSA26 Cre-ERT2* mice and resultant genotyping. Loss of Arid1a expression is expected following intraperitoneal injection of Tamoxifen.

Floxed *Arid1a* mice were a gift from Dr. Peri Tate, Sanger Institute, Hinxton UK; *ROSA26 Cre-ERT2* mice were a gift from Prof Chambon, IGBMC, France. ES-2 cells were purchased from ATCC and RMG-II were a gift from Prof Huntsman, British Columbia Cancer Agency, Vancouver, Canada.

###### Details of tissue and cell pellet used during the validation.

  ----------------------------------------------------------------
  Species   Tissue Type   Strain/Cell\       Details   Fixation\
                          line                         Time
  --------- ------------- ------------------ --------- -----------
  Murine    Uterus        C57Bl6             Female    16 hrs

  Murine    Uterus        C57Bl6 KO\         Female    24 hrs
                          *Arid1a ^fl/fl^*             

  Human     Cell Pellet   ES-2                         20 hrs

  Human     Cell Pellet   RMG-II                       20 hrs
  ----------------------------------------------------------------

Experiment details
------------------

***Western blot.*** Protein was extracted from the two clear cell carcinoma cell lines using a Tris-EDTA lysis buffer and run on a non-denaturing 3--8% Tris-acetate gel (Life Technologies). Following electrophoresis, the transfer membrane was probed with 0.2 µg/ml of anti-rabbit ARID1A (HPA005456) at 4°C overnight and 0.1 µg/ml anti-GAPDH (14C10) for the same length of time. Detection of the anti-rabbit ARID1A was with Goat anti-rabbit IRDye 680LT (Li-Cor Biosciences) and the GAPDH was with Goat anti-rabbit IRDye 800CW (Li-Cor Biosciences) both at 0.1 µg/ml.

***Immunohistochemistry.*** Slides were deparaffinised and rehydrated on a Leica ST5020 using Xylene (Sigma) for 2 × 10 mins and ethanol (Fisher), 2 × 100% ethanol followed by 1 × 70% ethanol for 5 mins each. Following staining, all slides were dehydrated, cleared and mounted and coverslipped in DPX (Fisher).

The antibody was validated on a Leica BondMax instrument using a Leica Intense R kit to a standardised in-house protocol. All reagents were from Leica as part of the Intense R kit and were conducted at room temperature, unless otherwise specified. All staining steps included individual washes in Leica Bond Wash after each step, as part of the protocol ( [Table 4](#T4){ref-type="table"}). A full protocol for the validated conditions can be found in the [supplementary material](#S1){ref-type="other"}. In this protocol, the step named "primary" refers to the anti-ARID1a primary antibody.

###### Staining protocol for ARID1A immunohistochemistry.

  -----------------------------------------------
  Protocol steps        Reagent          Time\
                                         (mins)
  --------------------- ---------------- --------
  Antigen Retrieval     ER1              20

  Or ER2                20               

  Or Enz1               10               

  Staining              Peroxide Block   5

  Avidin                10               

  Biotin                10               

  ARID1A                15               

  Donkey anti-rabbit\   8                
  Biotin                                 

  SA-HRP                8                

  DAB                   5                

  DAB Enhancer          10               

  Counterstaining       Haematoxylin     5
  -----------------------------------------------

A slide using the same conditions and retrieval but omitting the primary antibody was used to control for any background staining due to the retrieval and detection steps.

***Imaging.*** All slides were digitised using a Leica Scanscope AT2 at 0.5 µm/pixel resolution. Datasets can be viewed by downloading the Leica Imagescope free viewer at <http://www.leicabiosystems.com/pathology-imaging/aperio-epathology/integrate/imagescope/>.

Results
=======

To determine the correct cell line to utilise and to confirm the equivocal Western blot data from Human Protein Atlas, the antibody was used to stain a Western blot of two cell lines; ES-2 and RMG-II, both of which are cell lines derived from clear cell carcinoma and have been previously demonstrated as ARID1a wild-type and mutated, respectively ^[@ref-9]^. It could be demonstrated that the HPA ARID1A antibody showed positive expression in ES-2 cell lines at the expected size of 270 kDa and no staining for RMG-II. The loading control of GAPDH showed that there were no loading issues ( [Figure 1](#f1){ref-type="fig"}). Thus, these cell lines were chosen to be grown, formalin fixed and processed into paraffin wax for immunohistochemical validation.

![Western blot of ES2 and RMG-II clear cell carcinoma cells lines.\
ARID1A ( **red band**) can be seen to be present at approximately 270kD in ES2 cell line only. GAPDH at 37kD ( **green band**) represents loading control.](f1000research-3-6423-g0000){#f1}

For immunohistochemical validation, ES-2 and RMG-II cell lines were stained using three antigen retrieval conditions; ER1 (Sodium Citrate, pH6), ER2 (Tris/EDTA, pH9) and Enzyme 1 (Proteinase K, 100 µg/ml) at a fixed antibody concentration of 1 µg/ml. The enzyme retrieval demonstrated no nuclear signal for either ES2 or RMG-II cell pellets and was discarded for future work ( [Figure 2](#f2){ref-type="fig"}; [Dataset a](#DS0){ref-type="other"}). The ER2 condition did demonstrate significant nuclear staining in the ES2 cell pellet with minimal background staining in the RMG-II cell pellet ( [Figure 2](#f2){ref-type="fig"}; [Dataset b](#DS0){ref-type="other"}). However, the staining in the ER1 condition was determined to give the best signal:noise ratio with no background cytoplasmic staining and crisp nuclear staining for the cell pellet ( [Figure 2](#f2){ref-type="fig"}; [Dataset c](#DS0){ref-type="other"}). Control slides, omitting the primary antibody, were negative except for the ER2 condition in the RMG-II cell pellet where a weak cytoplasmic background could be seen ( [Figure 2](#f2){ref-type="fig"}; [Dataset d](#DS0){ref-type="other"}). Thus there was minimal background inherent in the staining procedure. It was therefore determined that the antibody showed specificity for formalin-fixed paraffin embedded tissues and could be run on murine tissue.

![ES2 and RMG-II cell lines stained by immunohistochemistry with anti-ARID1A using three antigen retrieval conditions, ER1, ER2 and Enzyme 1.\
NPA denotes No Primary antibody control and represents the ER2 condition. Bar = 200 µm.](f1000research-3-6423-g0001){#f2}

Murine uterine tissue was used as positive control tissue samples, given the literature data on cell lines and endometrial tissue. The ER1 condition at 1 µg/ml demonstrated clean nuclear staining in the uterine epithelial compartment as well as nuclear staining of stromal cells. However, the nuclear staining in the stroma was not universal and distinct negative nuclei could be seen ( [Figure 3A](#f3){ref-type="fig"}; [Dataset e](#DS0){ref-type="other"}). There was no cytoplasmic or extracellular stromal background staining present and the antibody titrated successfully losing the intensity of staining, as expected ( [Dataset e](#DS0){ref-type="other"}). Following this, a concentration of 0.5 µg/ml was used for future preparations which provided clear and consistent staining in repeated batches using a different antibody lot ( [Dataset f](#DS0){ref-type="other"}). A No Primary antibody control (NPA) showed no staining in the epithelial or nuclear compartment ( [Figure 3B](#f3){ref-type="fig"}; [Dataset e](#DS0){ref-type="other"}).

![**A**) Murine uterine tissue stained by immunohistochemistry with anti-ARID1A using the ER1 condition and a concentration of 1 ug/ml demonstrating clear nuclear staining of the epithelial compartment ( **E**) and negative nuclei in the stromal compartment ( **S**). **B**) No primary antibody control of a similar area of epithelium/stroma. Bar = 100 µm.](f1000research-3-6423-g0002){#f3}

Finally, when applied to a genetically engineered, tamoxifen-induced, Arid1a knockout mouse model, the staining in the uterine epithelium could be almost completely abrogated (Arrow, [Figure 4b](#f4){ref-type="fig"}) when compared to the same area in a wild-type animal (Arrow, [Figure 4a](#f4){ref-type="fig"}) with a small focal area of epithelial staining still present. There was no effect of the KO on the staining in the stromal compartment.

![Murine uterine tissue stained by immunohistochemistry with anti-ARID1A demonstrating nuclear staining in wild-type mice ( **A**) but loss of epithelial staining after ARID1A knock-out in *Arid1a ^fl/fl^* mice ( **B**). Bar = 100 μm.](f1000research-3-6423-g0003){#f4}

###### 

Detailed legends for each dataset (Datasets a--f) can be found in the text file provided. For Version 2 an additional image was added to Dataset e.

###### 

Click here for additional data file.

Conclusions
===========

It is clear from the use of ES2 and RMG-II cell lines that the Atlas Antibodies ARID1A antibody is specific for ARID1A in both Western blots and formalin-fixed paraffin embedded preparations of human origin and, coupled with the literature evidence, that it is validated in human tissue.

The staining pattern when applied to murine uterus showing a clear nuclear pattern, where there is a high level of sequence homology between the two species, is again consistent with the literature on this protein. When stained on an ARID1a knockout mouse model, the staining could be almost completely abrogated in the epithelial compartment but not in the stroma. Knockout mice generated in this manner are almost never 100% complete as in some cells recombination will not be induced due to issues such as low ligand (Tamoxifen) penetration or failure of the ligand to induce recombination, thus explaining the small focal area of epithelial staining. The difference in staining in the two compartments is also likely related to the same effect, as all other controls, such as omission of primary antibody remained negative. Thus, given the overwhelming data from other sources, it is likely the stromal staining reflects continuing Arid1a expression in this specific model system.

Therefore, in conclusion when taken in combination, it is clear that the anti-human ARID1a antibody is cross-reactive with murine tissue and can be used for this purpose.

Data availability
=================

F1000Research: Dataset 1. Whole slide images from antibody validation of HPA005456 for immunohistochemistry - Version 2, [10.5256/f1000research.5514.d41579](http://dx.doi.org/10.5256/f1000research.5514.d41579) ^[@ref-10]^
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